Primary systemic anaplastic large-cell lymphoma (CD30+): Advances in biology and current therapeutic approaches

Clinical Lymphoma

Volumn 2, Issue 1, 2001, Pages 29-37

  Fiorani, C ^a   Vinci, G ^a   Sacchi, S ^a   Bonaccorsi, G ^a   Artusi, T ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

(2; 5) translocation; ALK; CD30; Ki 1; Non Hodgkin's lymphoma; Nucleophosmin

Indexed keywords

AMSACRINE; ANAPLASTIC LYMPHOMA KINASE; BLEOMYCIN; CARMUSTINE; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HYBRID PROTEIN; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 3; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; PHENOTYPE; PROGNOSIS; PROTEIN VARIANT; STEM CELL TRANSPLANTATION; T CELL LYMPHOMA;

EID: 0034917479     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2001.n.009     Document Type: Review

References (61)

1. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
2. Updated Kiel classification for lymphomas
3. Diffuse large cell lymphomas of B and T cell type
4. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
5. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma')
6. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
7. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum
8. ALK-positive lymphoma: A single disease with a broad spectrum of morphology
9. Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases
10. Anaplastic large cell lymphoma and its morphological variants
11. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation
12. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features
13. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma
14. Transformation of the small cell variant Ki-1+ lymphoma to anaplastic large cell lymphoma: Pathologic and clinical features
15. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1+ with a high content of reactive histiocytes)
16. Lymphohistiocytic T-cell lymphoma and peripheral T-cell lymphoma associated with haemophagocytic syndrome: Two recently recognized entities which mimic malignant histiocytosis
17. The distinction of Hodgkin's disease from anaplastic large cell lymphoma
18. Anaplastic large cell lymphoma: A clinicopathologic analysis
19. Anaplastic large cell lymphomas expressing the novel chimeric protein p80 NPM/ALK: A distinct clinicopathologic entity
20. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements
21. Analysis of the t(2;5) (p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease
22. ALK+ lymphoma: Clinico-pathological findings and outcome
23. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
24. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy
25. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report
26. Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: Implications for the differential diagnosis between lymphoid and non-lymphoid malignancies
27. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis
28. Anaplastic large-cell lymphoma: Clinical and prognostic evaluation of 90 adult patients
29. Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome
30. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma
31. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation
32. Anaplastic large cell lymphoma: A distinct molecular pathologic entity: A reappraisal with special reference to p80(NPM/ALK) expression
33. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
34. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about
35. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1
36. [The many faces of anaplastic large cell lymphoma]
37. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations
38. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK
39. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35)
40. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation
41. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
42. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
43. Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation
44. Anaplastic large cell lymphoma: A clinicopathologic study of 53 cases
45. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies
46. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma
47. Anaplastic large cell lymphoma (CD30+/Ki-1+): Results of a prospective clinico-pathological study of 69 cases
48. Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among the Japanese
49. Primary Ki-1 anaplastic large-cell lymphoma in adults: Clinical characteristics and therapeutic outcome
50. Ki-1 lymphoma and Hodgkin's disease
51. Anaplastic large cell lymphoma Hodgkin's-like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy
52. Sequential intensive treatment with the F-MAHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1) positive anaplastic large cell lymphoma in adults
53. The therapy of primary adult systemic CD30 positive anaplastic large cell lymphoma: Results of 40 cases treated in a single center
54. Autologous stem cell transplantation for anaplastic large-cell lymphomas: Results of a prospective trial
55. A predictive model for aggressive non-Hodgkin's lymphoma
56. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
57. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin
58. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma
59. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases
60. Leukocyte protein tyrosine kinases: Potential targets for drug discovery
61. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid